Overview

Phase II Dose Ranging Study of Artesunate

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effective treatment regimen as determined by rapidity of parasite clearance by microscopy.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Office of the Surgeon General
Collaborators:
Military Infectious Diseases Research Program (MIDRP)
U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command
Treatments:
Artemisinins
Artesunate